Covid-19 and Porphyria

The American Porphyria Foundation will continue to share updates regarding COVID-19 in collaboration with the expert physicians of the Porphyrias Consortium and our pharmaceutical partners.

In general, patients with porphyrias, unless they also have heart, lung, kidney, or liver disease and/or are receiving immunosuppressive therapy or chemotherapy for non-porphyric diseases, are NOT at increased risk for contracting Covid-19 infection, nor at increased risk for adverse outcomes if they do.


Generally, there is no evidence that any vaccines cause particular problems in people with porphyrias. As a general rule, we therefore recommend that patients with any type porphyria receive vaccinations, in accordance with established guidelines, and under the care and follow-up of their personal physicians.

It is the unanimous opinion of the expert physicians of the Porphryias Consortium that it is important for all porphyria patients to receive the COVID-19  vaccinations , unless their personal physicians have indicated that, in their particular medical situations, not including porphyria, vaccination is not recommended.

The APF remains open and available to support your needs and questions during the COVID-19 pandemic. Please contact 866-APF-3635 or


UPDATE December 28, 2020


Update: Thursday, April 9, 2020


Porphyrias Consortiums expert, Dr. Bruce Wang, University of California San Francisco (UCSF), shares a video message with the porphyria community regarding COVID-19. Dr. Wang reviews the effects of the virus on patients with porphyria, and also advises on preventative care measures.